Biotage Invests in Biomolecules
Biotage AB has announced the purchase of shares in the Danish biomolecule company Chreto Aps, representing a significant investment into the area of drug development.
Biotage AB (Uppsala, Sweden) has announced the purchase of shares in the Danish biomolecule company Chreto Aps, representing a significant investment into the area of drug development.
Biomolecules are one of the fastest growing areas in drug development today, offering potential treatments to medical conditions poorly served by traditional pharmaceuticals.
“This investment makes an exciting part of our long-term strategic efforts,” explained Torben Jörgensen, CEO of Biotage. “We already have products for drug development based on peptides and are now taking one step further towards strengthening Biotage’s future offering in the biomolecule purification area.”
The deal, which sees Biotage own approximately 22% of Chreto, allows Biotage access to a wealth of biomolecule purification knowledge, as well as novel and patent protected technology.
For more information on Biotage please visit: www.biotage.com
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
